Affymax in $42M placing

23 February 2009

California, USA-based Affymax says it has obtained a commitment from institutional investors to purchase around $42.0 million of its common  stock in a private placement.

Under the terms of one of two types of purchase agreements, Affymax will  sell 2,844,708 newly-issued shares at a price of $11.25 each. In the  other purchase accord, the company will sell 652,262 newly-issued units  at $15.33 each, with each consisting of one share of common stock and  one warrant to buy 0.65 of a share of common stock. The warrants are  immediately exercisable at $16.78 per share and will expire five years  from the date of issuance.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight